DigiFab is an antidote for digoxin toxicity. It works by binding to digoxin and preventing it from working in the body.
Paladin Labs president and CEO Jonathan Ross Goodman said DigiFab provides an important opportunity to grow Paladin’s specialty and orphan franchise which includes Replagal, Elaprase and Antizol.
"Following approval, DigiFab will provide patients and physicians with a new option for the treatment digoxin poisoning," Goodman said.
Protherics has licensed DigiFab marketing rights to Paladin Labs in Canada.